Imaging of glutamate neurotransmitter alterations in Alzheimer's disease.
Publication/Presentation Date
4-1-2013
Abstract
Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP-PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild-type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through (1) H MRS. A positive correlation was observed between GluCEST contrast and (1) H MRS-measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease-modifying therapies for AD.
Volume
26
Issue
4
First Page
386
Last Page
391
ISSN
1099-1492
Published In/Presented At
Haris, M., Nath, K., Cai, K., Singh, A., Crescenzi, R., Kogan, F., Verma, G., Reddy, S., Hariharan, H., Melhem, E. R., & Reddy, R. (2013). Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. NMR in biomedicine, 26(4), 386–391. https://doi.org/10.1002/nbm.2875
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
23045158
Department(s)
Administration and Leadership
Document Type
Article